SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …

Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of
immune escape, challenging the present COVID-19 prophylaxis and clinical interventions …

Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread
around the world, there is an urgent need for new assay formats to characterize the humoral …

Despite the recent availability of vaccines against severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …